Literature DB >> 2729934

Safety and tolerance of ocular administration of recombinant alpha interferon.

R B Turner1, F J Durcan, J K Albrecht, A S Crandall.   

Abstract

The safety, tolerance, and levels of drug in the nasal cavity produced by an ocular formulation of interferon were determined at four dosages in a placebo-controlled, double-masked trial. Interferon given by the ocular route was generally well tolerated, although a dose-related occurrence of subjective symptoms was detected.

Mesh：

Substances：

Year:  1989        PMID： 2729934      PMCID： PMC171501          DOI： 10.1128/AAC.33.3.396

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon.

Authors:  F G Hayden; J K Albrecht; D L Kaiser; J M Gwaltney
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

2.  Sites of virus recovery and antigen detection in epithelial cells during experimental rhinovirus infection.

Authors:  R B Turner; B Winther; J O Hendley; N Mygind; J M Gwaltney
Journal:  Acta Otolaryngol Suppl       Date:  1984

3.  Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha 2 in natural respiratory viral infections.

Authors:  F G Hayden; J M Gwaltney; M E Johns
Journal:  Antiviral Res       Date:  1985-04       Impact factor: 5.970

4.  Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting.

Authors:  R M Douglas; B W Moore; H B Miles; L M Davies; N M Graham; P Ryan; D A Worswick; J K Albrecht
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

5.  Sites of rhinovirus recovery after point inoculation of the upper airway.

Authors:  B Winther; J M Gwaltney; N Mygind; R B Turner; J O Hendley
Journal:  JAMA       Date:  1986-10-03       Impact factor: 56.272

6.  Intranasally applied recombinant leukocyte A interferon in normal volunteers. II. Determination of minimal effective and tolerable dose.

Authors:  T C Samo; S B Greenberg; J M Palmer; R B Couch; M W Harmon; P E Johnson
Journal:  J Infect Dis       Date:  1984-08       Impact factor: 5.226

7.  Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection.

Authors:  A S Monto; T C Shope; S A Schwartz; J K Albrecht
Journal:  J Infect Dis       Date:  1986-07       Impact factor: 5.226

8.  Prevention of experimental coronavirus colds with intranasal alpha-2b interferon.

Authors:  R B Turner; A Felton; K Kosak; D K Kelsey; C K Meschievitz
Journal:  J Infect Dis       Date:  1986-09       Impact factor: 5.226
  8 in total
  1 in total

Review 1.  Clinical pharmacokinetics of interferons.

Authors:  R J Wills
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.